eTable. Pharmacokinetics and pharmacodynamics of the direct or non-vitamin-K-dependent oral anticoagulants currently on the market (data from [5] and summaries of product characteristics).

	Apixaban	Rivaroxaban	Edoxaban	Dabigatran
Point of action	Factor Xa	Factor Xa	Factor Xa	Factor IIa (thrombin)
Prodrug	No	No	No	Yes
Time to Cmax (h)	1–3 (4)	2–4	1–2	2–3
CYP metabolism	15%	32%	<4%	0%
Bioavailability	(50% ?) 66%	80%	62%	3–7%
Transport	P-gp	P-gp/BCRP	P-gp	P-gp
Protein binding	87%	> 90%	55%	35%
Half-life (h)	8–15	(5–7 ?) 9–13	10–14	(8?)12–14(15?)
Renal elimination	27%	33% (65%)*	50%	80%

^*Approximately half eliminated unchanged in the urine

BCRP. breast cancer resistant protein; Cmax. maximal concentration (peak level); CYP. cytochrome P450; P-gp. P-glycoprotein.

The question marks indicate uncertainty.